<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027647</url>
  </required_header>
  <id_info>
    <org_study_id>ATORG-003</org_study_id>
    <nct_id>NCT04027647</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Dacomitinib in NSCLC</brief_title>
  <official_title>A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the&#xD;
      efficacy and safety of first-line treatment with dacomitinib, with or without dose titration,&#xD;
      in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive&#xD;
      non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and&#xD;
      the rest of the participating sites are sponsors of their own individual sites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">March 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the start of treatment to the date of disease progression or death due to any cause at 12 months</time_frame>
    <description>Percentage of subjects with PFS at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the start of treatment to the date of death for any cause, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From the start of treatment until disease progression, up to 3 years</time_frame>
    <description>Proportion of subjects with a best overall response of either complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>From the start of treatment to the last dose of treatment, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Objective Response Rate</measure>
    <time_frame>From the start of treatment until disease progression, up to 3 years</time_frame>
    <description>Proportion of subjects with a best overall response of either CR or PR of intracranial disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Progression-Free Survival</measure>
    <time_frame>From the start of treatment to the date of intracranial progression or death due to any cause, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incidences of adverse events</measure>
    <time_frame>From start of treatment to 28 days after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>NSCLC Stage IIIB</condition>
  <condition>NSCLC Stage IIIC</condition>
  <condition>NSCLC Stage IV</condition>
  <condition>Recurrent NSCLC</condition>
  <condition>EGFR Positive Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily administration of oral Dacomitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <description>30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Vizimpro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of a voluntarily given, personally signed and dated, written informed&#xD;
             consent document;&#xD;
&#xD;
          -  Age ≥20 years in Japan and Korea, and ≥18 years in other countries, male or female;&#xD;
&#xD;
          -  The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in&#xD;
             exon 21) in tumor specimen determined by the local laboratory;&#xD;
&#xD;
          -  Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International&#xD;
             Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months&#xD;
             disease free interval between completion of systemic therapy and recurrence of NSCLC&#xD;
             required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically&#xD;
             accepted variants using tumor specimen (assessed according to accepted standards by a&#xD;
             local laboratory). For this purpose the World Health Organization/International&#xD;
             Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria&#xD;
             will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or&#xD;
             mixed adeno-squamous lung carcinomas will not be allowed;&#xD;
&#xD;
          -  Have an ECOG PS of 0 or 1;&#xD;
&#xD;
          -  No prior treatment with systemic therapy for locally advanced or metastatic NSCLC.&#xD;
             Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality&#xD;
             chemotherapy/radiation therapy permitted only in cases in which there is a minimum of&#xD;
             12 months disease free interval between completion of systemic therapy and recurrence&#xD;
             of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;&#xD;
&#xD;
          -  Radiologically measurable disease by RECIST v1.1 criteria:&#xD;
&#xD;
               1. At least one target lesion that has not previously been radiated, and is&#xD;
                  measurable according to RECIST v1.1;&#xD;
&#xD;
               2. Acceptable radiologic procedures for disease assessment include contrast enhanced&#xD;
                  conventional or spiral computed tomography (CT), or contrast enhanced magnetic&#xD;
                  resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who&#xD;
                  are both allergic to intravenous contrast and unable to cooperate with MRI, or&#xD;
                  MRI is not available. The following are not allowed as sole documentation of&#xD;
                  target lesions: CT component of positron emission tomography (PET)/CT, ultrasound&#xD;
                  alone, nuclear scans (including bone or PET scans), chest X-ray or bone&#xD;
                  radiographs, and tumor markers;&#xD;
&#xD;
          -  Adequate organ function, including:&#xD;
&#xD;
               1. Estimated creatinine clearance ≥30 mL/min (as determined by Cockcroft-Gault&#xD;
                  formula or the study site's standard formula);&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1500 cells/mm3;&#xD;
&#xD;
               3. Platelets ≥100,000 cells/mm3;&#xD;
&#xD;
               4. Hemoglobin ≥10.0 g/dL;&#xD;
&#xD;
               5. Bilirubin ≤1.5 x ULN;&#xD;
&#xD;
               6. AST (also known as SGOT) and ALT (also known as SGPT) ≤2.5 x ULN (≤5.0 x ULN if&#xD;
                  hepatic metastases).&#xD;
&#xD;
          -  Female subjects must be postmenopausal (defined as 12 months of amenorrhea following&#xD;
             last menses), or they or their partners must be surgically sterile, or must agree to&#xD;
             use effective contraception while receiving study treatment and for at least 3 months&#xD;
             thereafter. The definition of effective contraception will be based on the judgment of&#xD;
             the investigator using following criteria:&#xD;
&#xD;
             a. Acceptable contraception for women include implants, injectables, combined oral&#xD;
             contraceptives, intrauterine devices (IUDs), sexual abstinence, or a partner who has&#xD;
             been surgically sterile (e.g. by vasectomy) for at least 6 months. Acceptable&#xD;
             contraception for a male includes surgical sterility (e.g. by vasectomy) for at least&#xD;
             6 months, sexual abstinence, or condoms plus spermicide.&#xD;
&#xD;
          -  All female subjects with reproductive potential must have a negative pregnancy test&#xD;
             (serum or urine) prior to starting study treatment;&#xD;
&#xD;
          -  Male subjects or their female partners must be surgically sterile or must agree to use&#xD;
             effective contraception while receiving study treatment and for at least 3 months&#xD;
             thereafter. The definition of effective contraception will be based on the judgment of&#xD;
             the investigator. Or female partners must be postmenopausal (defined as 12 months of&#xD;
             amenorrhea following last menses);&#xD;
&#xD;
          -  Willing and able to comply with study scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of mixed histo- and/or cytology that includes elements of small cell or&#xD;
             carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous&#xD;
             element can be present;&#xD;
&#xD;
          -  An EGFR exon 20 T790M or exon 20 insertion mutation;&#xD;
&#xD;
          -  Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or&#xD;
             require increasing doses of steroids and/or anti-seizure medications to manage CNS&#xD;
             symptoms within two weeks prior to starting dacomitinib;&#xD;
&#xD;
          -  Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC&#xD;
             including but not limited to chemotherapy, targeted therapies, small molecules,&#xD;
             EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy,&#xD;
             radiotherapy (other than palliative radiotherapy to lesions that will not be followed&#xD;
             for tumor assessment on this study, i.e., non-target lesions). Completed&#xD;
             neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/&#xD;
             radiation therapy permitted only in cases in which there is a minimum of 12 months&#xD;
             disease free interval between completion of systemic therapy and recurrence of NSCLC.&#xD;
             Prior treatment with a EGFR-TKI or other TKIs is not allowed;&#xD;
&#xD;
          -  Any surgery (not including minor procedures such as lymph node biopsy), palliative&#xD;
             radiotherapy or pleurodesis within 2 weeks of baseline assessments;&#xD;
&#xD;
          -  Any clinically significant gastrointestinal abnormalities that may impair intake,&#xD;
             transit or absorption of the study drug, such as the inability to take oral&#xD;
             medication;&#xD;
&#xD;
          -  Current enrollment in another therapeutic clinical study;&#xD;
&#xD;
          -  Any psychiatric or cognitive disorder that would limit the understanding or rendering&#xD;
             of informed consent and/or compromise compliance with the requirements of this study;&#xD;
             or known drug abuse/alcohol abuse;&#xD;
&#xD;
          -  History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial&#xD;
             lung disease including:&#xD;
&#xD;
               1. Past medical history of interstitial lung disease, drug-induced interstitial&#xD;
                  disease, radiation pneumonitis which required steroid treatment or any evidence&#xD;
                  of clinically active interstitial lung disease;&#xD;
&#xD;
               2. Pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline;&#xD;
&#xD;
               3. Insufficient lung function as determined by either clinical examination or an&#xD;
                  arterial oxygen tension of &lt;70 Torr.&#xD;
&#xD;
          -  Any history of rare hereditary problems of galactose intolerance, total lactase&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          -  Clinically important abnormalities in cardiac rhythm, conduction or morphology of&#xD;
             resting ECG (e.g. complete left bundle branch block, second degree heart block, third&#xD;
             degree heart block) OR:&#xD;
&#xD;
               1. Diagnosed or suspected congenital long QT syndrome;&#xD;
&#xD;
               2. Any history of clinically significant ventricular arrhythmias (such as&#xD;
                  ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);&#xD;
&#xD;
               3. Prolonged QTc interval on ECG; QTc must be less than CTCAE v5.0 Grade 2 (≤480&#xD;
                  msec) using Fridericia's or Bazett's correction formula with a manual reading by&#xD;
                  the investigator if required. The ECG may be repeated for evaluation of&#xD;
                  eligibility after management of correctable causes for observed QTc prolongation;&#xD;
&#xD;
               4. Any history of second or third degree heart block;&#xD;
&#xD;
               5. Heart rate &lt;45 beats per minute on ECG in the presence of clinical symptoms&#xD;
                  (e.g., hypotension, evidence of hypoperfusion);&#xD;
&#xD;
          -  Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;&#xD;
&#xD;
          -  Prior malignancy: Subjects will not be eligible if they have history of, or evidence&#xD;
             of active disease of another concurrent malignancy within the previous five years.&#xD;
             Exception would be effectively treated past history of non-melanoma skin cancer or&#xD;
             in-situ cervical cancer with no evidence of active disease;&#xD;
&#xD;
          -  Other severe acute or chronic medical condition that may increase the risk associated&#xD;
             with study participation or study drug administration or may interfere with the&#xD;
             interpretation of study results and, in the judgment of the investigator, would make&#xD;
             the subject inappropriate for entry into this study;&#xD;
&#xD;
          -  Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6&#xD;
             substrate may lead to serious or life-threatening toxicities, including but not&#xD;
             limited to procainamide, pimozide, and thioridazine from screening to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Tan, BSc, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre Singapore (Lead Sponsor)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Tan, BSc, MBBS, PhD</last_name>
    <phone>+65 6436 8000</phone>
    <email>daniel.tan.s.w@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herbert Loong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suee Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong-Wan Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yueh Ni Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gwo Fuang Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beacon Hospital</name>
      <address>
        <city>Petaling Jaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lye Mun Tho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naiyarat Prasongsook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thanyanan Reungwetwattana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage III NSCLC</keyword>
  <keyword>Stage IV NSCLC</keyword>
  <keyword>Vizimpro</keyword>
  <keyword>EGFR TKI</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

